DK2968281T3 - Mtor-hæmmere til forebyggelse af vækst af tarmpolyp - Google Patents

Mtor-hæmmere til forebyggelse af vækst af tarmpolyp Download PDF

Info

Publication number
DK2968281T3
DK2968281T3 DK14772920.6T DK14772920T DK2968281T3 DK 2968281 T3 DK2968281 T3 DK 2968281T3 DK 14772920 T DK14772920 T DK 14772920T DK 2968281 T3 DK2968281 T3 DK 2968281T3
Authority
DK
Denmark
Prior art keywords
polyph
intestinal
growth
preventing
mtor inhibitors
Prior art date
Application number
DK14772920.6T
Other languages
English (en)
Inventor
Zelton Dave Sharp
Randy Strong
Paul Hasty
Carolina Livi
Arlan Richardson
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK2968281T3 publication Critical patent/DK2968281T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK14772920.6T 2013-03-13 2014-03-13 Mtor-hæmmere til forebyggelse af vækst af tarmpolyp DK2968281T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778670P 2013-03-13 2013-03-13
PCT/US2014/026329 WO2014160328A1 (en) 2013-03-13 2014-03-13 Mtor inhibitors for prevention of intestinal polyp growth

Publications (1)

Publication Number Publication Date
DK2968281T3 true DK2968281T3 (da) 2020-11-02

Family

ID=51625398

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14772920.6T DK2968281T3 (da) 2013-03-13 2014-03-13 Mtor-hæmmere til forebyggelse af vækst af tarmpolyp

Country Status (4)

Country Link
US (5) US20160030401A1 (da)
EP (1) EP2968281B1 (da)
DK (1) DK2968281T3 (da)
WO (1) WO2014160328A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
EP3089737B1 (en) * 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
WO2018141810A1 (en) * 2017-01-31 2018-08-09 Alf Lamprecht Use of nanoparticles for immunotherapy

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US5206018A (en) 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US5066493A (en) 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
JPS57147430A (en) 1981-03-06 1982-09-11 Kureha Chem Ind Co Ltd Preparation of microcapsule
US4401653A (en) 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5120726A (en) 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5358944A (en) 1990-09-19 1994-10-25 American Home Products Corporation Rapamycin esters for treating transplantation rejection
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5286731A (en) 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5262424A (en) 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5260299A (en) 1992-03-05 1993-11-09 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-Carboalkoxy)Sulfamates Useful as Immunosuppressive Agents
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5288711A (en) 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
JP3277342B2 (ja) 1992-09-02 2002-04-22 武田薬品工業株式会社 徐放性マイクロカプセルの製造法
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5310903A (en) 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ATE398448T1 (de) 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
SK78196A3 (en) 1993-12-17 1997-02-05 Sandoz Ag Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5504291A (en) 1994-02-14 1996-04-02 Square D Company Contact blade assembly for a circuit breaker
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
EP0759750A4 (en) 1994-05-11 1998-05-27 Howard K Shapiro PREPARATIONS FOR TREATING CHRONIC FLAMMABLE DISEASES
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US7132458B2 (en) 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5985890A (en) 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
JP3545148B2 (ja) 1996-01-08 2004-07-21 味の素株式会社 食用マイクロカプセル及びそれを含有する食品
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6117911A (en) 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
WO1999044642A1 (en) 1998-03-05 1999-09-10 Phares Pharmaceutical Research Nv Pharmaceutical compositions and their use
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US7455853B2 (en) 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6653256B1 (en) 1999-08-24 2003-11-25 Bayer Aktiengesellschaft Microcapsule formulations
BR0015491A (pt) 1999-11-12 2002-10-15 Oncolytics Biotech Inc Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
ATE235960T1 (de) 2000-01-13 2003-04-15 Kureha Chemical Ind Co Ltd Mikrokapsel und sein herstellungsverfahren
EP1250135B1 (en) 2000-01-14 2010-07-28 The Trustees of The University of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
US6974473B2 (en) 2000-06-30 2005-12-13 Vascular Architects, Inc. Function-enhanced thrombolytic AV fistula and method
DE10035302C2 (de) 2000-07-18 2002-12-19 Deotexis Inc Mikrokapsel, Verfahren zu ihrer Herstellung und Verwendung derselben
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
GB0103668D0 (en) 2001-02-15 2001-03-28 Biointeractions Ltd Methods and clinical devices for the inhibition or prevention of mammalian cell growth
US7018371B2 (en) 2001-05-07 2006-03-28 Xoft, Inc. Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia
US6537195B2 (en) 2001-05-07 2003-03-25 Xoft, Microtube, Inc. Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US7056338B2 (en) 2003-03-28 2006-06-06 Conor Medsystems, Inc. Therapeutic agent delivery device with controlled therapeutic agent release rates
EP1419153A1 (en) 2001-08-22 2004-05-19 Wyeth Rapamycin dialdehydes
DK1419154T3 (da) 2001-08-22 2006-01-09 Wyeth Corp Rapamycin-29-enoler
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US7008979B2 (en) 2002-04-30 2006-03-07 Hydromer, Inc. Coating composition for multiple hydrophilic applications
US20050240145A1 (en) 2002-04-30 2005-10-27 Neal Scott Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US7037582B2 (en) 2002-05-28 2006-05-02 The Hong Kong Polytechnic University Method for encapsulating phase transitional paraffin compound that can undergo phase transition and microcapsule resulting therefrom
US6881810B2 (en) 2002-07-15 2005-04-19 Fuji Photo Film Co., Ltd. Microcapsule and process for manufacturing the same
AU2003266525A1 (en) 2002-09-18 2004-04-08 Koyama, Yuu Process for producing microcapsule
US6936644B2 (en) 2002-10-16 2005-08-30 Cookson Electronics, Inc. Releasable microcapsule and adhesive curing system using the same
WO2004050090A1 (en) 2002-11-29 2004-06-17 Maria Grazia Roncarolo Rapamycin and il-10 for the treatment of immune diseases
US7517342B2 (en) 2003-04-29 2009-04-14 Boston Scientific Scimed, Inc. Polymer coated device for electrically medicated drug delivery
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
UA84881C2 (ru) 2003-09-03 2008-12-10 Уайт Аморфный 42-эфир рапамицина и 3-гидрокси-2-(гидроксиметил)-2-метилпропионовой кислоты и фармацевтическая композиция, содержащая его
GB0323202D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US20050113282A1 (en) 2003-11-20 2005-05-26 Parekh Prabodh P. Melamine-formaldehyde microcapsule slurries for fabric article freshening
PL1735321T3 (pl) 2004-04-14 2009-04-30 Wyeth Corp Proces wytwarzania 42-estrów rapamycyny i 32-estrów FK-506 z kwasem dikarboksylowym, prekursory koniugatów rapamycyny oraz przeciwciała
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
GB2413824A (en) 2004-05-07 2005-11-09 Statoil Asa Operating diesel-cycle i.c. engines on gaseous fuels with ignition-improvers
AU2005247195A1 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
KR100555881B1 (ko) 2004-07-21 2006-03-03 오준택 잠열저장물질을 함유한 마이크로캡슐의 제조방법
AR050374A1 (es) 2004-08-20 2006-10-18 Wyeth Corp Forma polimorfica de rafampicina
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
CA2590675A1 (en) 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
NZ574663A (en) 2004-12-20 2010-05-28 Wyeth Corp Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders
DK1848431T3 (da) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd Flydende formuleringer til behandling af sygdomme eller tilstande
AU2006221046B2 (en) 2005-03-03 2012-02-02 Icon Medical Corp. Improved metal alloys for medical device
CA2602010A1 (en) 2005-03-07 2006-09-14 Wyeth Oxepane isomer of 42-o-(2-hydroxy)ethyl-rapamycin
BRPI0608573A2 (pt) 2005-03-08 2017-07-25 Lifecycle Pharma As Composição farmacêutica, e, método para a preparação de uma composição farmacêutica.
GB0504994D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
MX2007011494A (es) 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
JP5034298B2 (ja) 2005-04-19 2012-09-26 セイコーエプソン株式会社 マイクロカプセル、マイクロカプセルの製造方法、電気泳動表示装置および電子機器
RU2426774C2 (ru) 2005-09-27 2011-08-20 Дзе Проктер Энд Гэмбл Компани Чистящая и моющая композиция и способы её получения и применения
WO2007056175A2 (en) 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
WO2007059106A2 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
US20070138673A1 (en) 2005-12-15 2007-06-21 Kaiping Lee Process for Preparing a High Stability Microcapsule Product and Method for Using Same
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
EP2520287B1 (en) 2006-02-10 2025-03-26 Boston Scientific Medical Device Limited Loading of hydrophobic drugs into hydrophilic polymer delivery systems
US20090023805A1 (en) 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
US20070203168A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US7622477B2 (en) 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
US20070225313A1 (en) 2006-02-28 2007-09-27 Zhao Jonathon Z Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same
US20070203171A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same
US20070203169A1 (en) 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
WO2008022256A2 (en) 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
US20080138405A1 (en) 2006-12-06 2008-06-12 Raheja Praveen Sirolimus nanodispersion
EP1952807A1 (en) 2007-01-24 2008-08-06 LEK Pharmaceuticals D.D. Sirolimus formulation
MX2009010683A (es) 2007-04-05 2010-01-20 Wyeth Corp Conjugado de wortmanina-rapamicina y usos del mismo.
US20110104256A1 (en) 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
MX2011004199A (es) 2008-10-20 2011-05-24 Abbott Lab Anticuerpos que unen a il-18 y metodos para purificar los mismos.
WO2010049481A1 (en) 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
ES2645692T3 (es) * 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
WO2010144846A2 (en) * 2009-06-13 2010-12-16 The Salk Institute For Biological Studies Gastrointestinal disease or disorder imaging and treatment
WO2011034606A1 (en) 2009-09-19 2011-03-24 Wu Nian Pharmaceutical compositions of rapamycin
KR101267813B1 (ko) 2009-12-30 2013-06-04 주식회사 삼양바이오팜 향상된 수용해도를 갖는 라파마이신 함유 고분자나노입자 주사제형 조성물 및 그 제조방법, 및 방사선 요법과 병용하기 위한 항암 조성물
DE102010002769A1 (de) 2010-03-11 2011-09-15 Osram Gesellschaft mit beschränkter Haftung Elektrische Lampe mit einem Außenkolben und einer Einbaulampe und zugehöriges Herstellverfahren
US8157311B2 (en) 2010-03-11 2012-04-17 Ford Global Technologies, Llc Vehicular trim panel with storage and interfacing of electronic devices
CN102834094B (zh) * 2010-04-16 2015-05-06 诺华有限公司 有机化合物的组合产品及其制药用途
WO2014160328A1 (en) * 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) * 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Also Published As

Publication number Publication date
WO2014160328A1 (en) 2014-10-02
US12383538B2 (en) 2025-08-12
US20170105974A1 (en) 2017-04-20
US20200330442A1 (en) 2020-10-22
US20220096446A1 (en) 2022-03-31
US20160030401A1 (en) 2016-02-04
EP2968281A4 (en) 2016-09-07
US11191750B2 (en) 2021-12-07
US20260014124A1 (en) 2026-01-15
EP2968281B1 (en) 2020-08-05
EP2968281A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
IL250923A0 (en) Novel compounds as rearranged during transfection (ret) inhibitors
DK3300610T3 (da) Fremgangsmåde til fraktionering af opløselige ærter
DK2964315T3 (da) System til behandling af neuromotorisk dysfunktion
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
DK2996556T3 (da) System til billedstyret procedure
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3119772T3 (da) Heteroaryl syk-hæmmere
DK3395814T3 (da) Hæmmere af fibroblastvækstfaktorreceptoren
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3066085T3 (da) Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor
DK3027618T3 (da) Polymorf af syk-hæmmere
LT4275756T (lt) Bipirazolo dariniai kaip jak inhibitoriai
EP2948458A4 (en) BTK INHIBITORS
DK3057962T3 (da) Hydrochloridsaltform til ezh2-hæmning
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
EP2948431A4 (en) BTK INHIBITORS
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2953904T3 (da) Fremgangsmåde til kontrolleret fremstilling af et biocid
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
EP3394068A4 (en) TDO2 INHIBITORS